|Natural Approaches In the Treatment of Congestive Heart Failure|
By Dr. Sergey A. Dzugan
Testosterone therapy has been proposed as an additional treatment for men with CHF.67 Testosterone reduces blood pressure and enhances relaxation of brachial arteries; direct injection of testosterone into the coronary arteries produces dilatation and increased coronary blood flow.68-70 The resulting vasodilator effect may relieve pulmonary congestion and improve peripheral perfusion. Androgen therapy could also improve cardiac function by reducing the stress on the heart muscle both before and after contraction as well as by increasing coronary blood flow. Additionally, androgen therapy is useful in augmenting skeletal muscle strength in CHF patients.71 Androgen replacement therapy could potentially alleviate symptoms by improving cardiac and vascular function as well as by increasing strength and endurance. It may also redress the catabolic-anabolic imbalance of CHF and suppress the cytokine activation that leads to the disease’s progression.
Optimal levels of steroid hormones such as pregnenolone, DHEA, progesterone, estrogen, testosterone, and cortisol are necessary for maintaining optimal health in both males and females. Alteration in these hormones may play a significant role in CHF. In one study, patients received hormonorestorative therapy with hormones such as pregnenolone, DHEA, triestrogen gel, progesterone gel, and testosterone gel for correcting high levels of cholesterol.72 One hundred percent of the patients responded. This is because the human body contains all the enzymes and cofactors it needs to process natural hormones when they occur in their natural human proportions. Hormono-restorative therapy promises to be an important therapeutic protocol in the treatment of CHF, along with supplements that naturally enhance cardiac output.
1. Kromhout D. Diet and cardiovascular disease. J Nutr Health Aging 2001 5(3):144-9.
2. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive diseases management. Am Heart J. 1997 Jun;133(6):703-12.
3. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk fac- tors, and the rate of cardiovascular com- plications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999 Feb 16;99(6):779-85.
4. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999 Apr 6;130(7):554-62.
5. Hu FB, Stampfer MJ, Manson JE, et al. Dietary intake of alpha-linolenic acid and risk of fatal ischemic heart disease among women. Am J Clin Nutr. 1999 May;69(5):890-7.
6. Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997 Apr 10;336(15):1046-53.
7. Connor WE. Do the n-3 fatty acids from fish prevent deaths from cardiovascular disease? Am J Clin Nutr. 1997 Jul;66(1):188-9.
8. Albert CM, Hennekens CH, O’Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998 Jan 7;279(1):23-8.
9. McCarron DA, Oparil S, Chait A, et al. Nutritional management of cardiovascular risk factors. A randomized clinical trial. Arch Intern Med 1997 Jan 27;157(2):169-77.
10. Ness AR, Powles JW. Fruit and vegetables, and cardiovascular disease: a review. Int J Epidemiol 1997 Feb;26(1):1-13.
11. McDougall J, Litzau K, Haver E, Saunders V, Spiller GA. Rapid reduction of serum cholesterol and blood pressure by a twelve-day, very low fat, strictly vegetarian diet. J Am Coll Nutr 1995 Oct;14(5):491-6.
12. Wolk A, Manson JE, Stampfer MJ, et al. Long-term intake of dietary fiber and decreased risk of coronary heart disease among women. JAMA 1999 Jun 2;281(21):1998-2004.
13. Morelli V, Zoorob RJ. Alternative therapies: Part II. Congestive heart failure and hypercholesterolemia. Am Fam Physician 2000 Sept 15;62(6):1325-30.
14. Gavagan T. Cardiovascular disease. Prim Care 2002 Jun;29(2):323-38, vi.
15. Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements: therapeutic relevance to heart failure. Herz 2002 Mar;27(2):174-8.
16. Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care 2000 Nov;3(6):417-24.
17. Jeejeebhoy F, Keith M, Freeman M, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J 2002 Jun;143(6):1092-100.
18. Bagchi D. A review of the clinical ben-efits of coenzyme Q10. J Adv Med 1997 10:139-48.
19. Nayler WG. The use of coenzyme Q10 to protect ischaemic heart muscle. In Yamamura Y, Folkers K, Ito Y (eds): Biomedical and Clinical Aspects of Coenzyme Q, vol. 2. Amsterdam, Elsevier-North Holland Biomedical, 1980, pp. 409-25.
20. Awata N, et al. The effects of coenzyme Q10 on ischemic heart disease evaluated by dynamic exercise test. In Yamamura Y, Folkers K, Ito Y (eds): Biomedical and Clinical Aspects of Coenzyme Q, vol. 2. Amsterdam, Elsevier-North Holland Biomedical, 1980, pp. 247-54.
21. Nakamura Y, Takahashi M, Hayashi J, et al. Protection of ischaemic myocardium with coenzyme Q10. Cardiovasc Res 1982 Mar;16(3):132-7.
22. Crane FL, Navas P. The diversity of coenzyme Q function. Mol Aspects Med 1997 18 Suppl:S1-6.
23. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci USA 1990 Jun;87(12):4879-83.
24. Ondarroa M, Quinn PJ. Proton magnetic resonance spectroscopic studies of the interaction of ubiquinone-10 with phospholipid model membranes. Eur J Biochem 1986 Mar 3;155(2):353-61.
25. Yamamura Y, et al. Clinical use of coenzyme Q for treatment of cardiovascular disease. Jpn Circ J 1967 31:168.
26. Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990 Feb 16;65(7):521-3.
27. Judy WV, et al. Double blind double crossover study of coenzyme Q10 in heart failure. In Folkers K, Yamamura Y (eds): Biomedical and Clinical Aspects of Coenzyme Q, vol. 5. Amsterdam, Elsevier, 1986, pp. 315-22.
28. Langsjoen PH, Langsjoen AM. Overview of the use of coQ10 in cardiovascular disease. Biofactors 1999 9(2-4):273-84.
29. Soja AM, Mortensen SA. Treatment of chronic cardiac insufficiency with coenzyme Q10, results of meta-analysis in controlled clinical trials. Ugeskr Laeger 1997 Dec 1; 159(49):7302-8.
30. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig 1993 71(8 Suppl):S134-6.
31. Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994 15 Suppl:s287-94.
32. Langsjoen PH, Langsjoen AM. Coenzyme Q10 in cardiovascular disease with emphasis on heart failure and myocardial ischemia. Asia Pac Heart J 1998 7: 160-68.
33. Judy WV, Hall JH, Folkers K. Coenzyme Q10 withdrawal – clinical relapse in congestive heart failure patients. In Folkers K, Littaru GP, Yamagami T (eds): Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam, Elsevier Science, 1991, pp. 283-98.
34. Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int J Tissue React 1990 12(3):163-8.
35. Judy WV, Folkers K, Hall JH. Improved long-term survival in coenzyme Q10 treated chronic heart failure patients compared to conventionally treated patients. In Folkers K, Littarru GP, Yamagami T (eds): Biomedical and Clinical Aspects of Coenzyme Q, vol. 4. Amsterdam, Elsevier Science, 1991, pp. 291-98.
36. Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Prev Cardiol 2000 3(1):24-32.
37. Goa KL, Brogden RN. L-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 1987 34(1):1-24.
38. Mancini M, Rengo F, Lingetti M, Sorrentino GP, Nolfe G. Controlled study on the therapeutic efficacy of propionyl- L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992 Sept;42(9):1101-4.
39. Pucciarelli G, Mastursi M, Latte S, et al. The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure. Clin Ter 1992 Nov; 141(11):379-84.
40. Caponnetto S, Canale C, Masperone MA, Terracchini V, Valentini G, Brunelli C. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction. Eur Heart J 1994 Sept;15(9):1267-73.
41. Azuma J, et al. Double-blind randomized crossover trial of taurine in congestive heart failure. Curr Ther Res 1983 34(4):543-57.
42. Azuma J, et al. Therapeutic effect of taurine in congestive heart failure: A double-blind crossover trial. Clin Cardiol 1985 8:276-82.
43. Schaffer SW, Lombardini JB, Azuma J.Interaction between the actions of taurine and angiotensin II. Amino Acids 2000;18(4):305-18.
44. Fong HH, Bauman JL. Hawthorn. J Cardiovasc Nurs 2002 Jul;16(4):1-8.
45. Schmidt U, et al. Efficacy of the hawthorn (Crataegus) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. Phytomedicine 1994 1:17-24.
46. Weikl A, Assmus KD, Neukum-Schmidt A, et al. Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II). Fortschr Med 1996 Aug 30;114(24):291-6.
47. Leuchtgens H. Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study. Fortschr Med 1993 111(20- 21):352-4.
48. Tauchert M, Gildor A, Lipinski J. High- dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure. Herz 1999 24(6):465-74.
49. Busse W. Standardized Crataegus extract clinical monograph. Q Rev Nat Med 1996 189-97.
50. Weihmayr T, Ernst E. Therapeutic effectiveness of Crataegus. Fortschr Med 1996 114(1-2):27-9.
51. O’Conolly VM, et al. Treatment of cardiac performance (NYHA stages I to II) in advanced age with standardized cratae gus extract. Fortschr Med 1986 104:805-8.
52. Schussler M, Holzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneimittelforschung 1995 45(8):842-5.
53. Bahorun, T. Antioxidant activities of Crataegus monogyna extracts. Planta Medica 1994 60:323-8
54. Seelig MS. Interrelationship of magnesium and congestive heart failure. Wien Med Wochenschr 2000 150(15-16):335-41.
55. Cohen N, Alon I, Almoznino-Sarafian D,et al. Metabolic and clinical effects of oral magnesium supplementation in furosemide-treated patients with severe congestive heart failure. Clin Cardiol 2000 23(6):433-6.
56. Hix CD. Magnesium in congestive heart failure, acute myocardial infarction and dysrhythmias. J Cardiovasc Nurs 1993 8(1):19-31.
57. Suh JH, Shigeno ET, Morrow JD, et al. Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-(alpha)-lipoic acid. FASEB J. 2001 Mar;15(3):700-6.
58. Anker SD, Clark AL, Kemp M, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997 30(4):997-1001.
59. Muller J. Cholesterol, interactions with testosterone and cortisol in cardiovascular diseases. Berlin: Springer- Verlag; 1987
60. Noirhomme P, Jaquet L, Underwood M, et al. The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end-stage heart failure. Eur J Cardiothorac Surg 1999 16:63–7.
61. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997 96:526–34.
62. Tappler B, Katz M. Pituitary-gonadal dysfunction in low-output cardiac failure. Clin Endocrinol 1979 10(3):219–26.
63. Niebauer J, Pflaum C-D, Clark AL, et al. Deficient insulin-like growth factor 1 in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998 32:393–7.
64. Swan JW, Walton C, Godsland IF, et al. Insulin resistance in chronic heart failure. Eur Heart J 1994 15:1528–32.
65. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, et al. Hormonal profile in patients with congestive heart fail- ure. Int J Cardiol 2003 87(2-3):179-83.
66. Moriyama Y, Yasue H, Yoshimura M, et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 2000 85(5):1834-40.
67. Pugh PJ, English KM, Jones TH, Channer KS. Testosterone: a natural tonic for the failing heart? QJM 2000 93(10):689-94.
68. Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes 1992 16(12):991–7.
69. Ong PJ, Patrizi G, Chong WC, et al. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 2000 85(2):269–72.
70. Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coro- nary heart disease. Circulation 1999 100(16):1690–6.
71. Shapiro J, Christiana J, Frishman WH. Testosterone and other anabolic steroids as cardiovascular drugs. Am J Ther 1999 6(3):167-74.
72. Dzugan SA, Arnold Smith R. Hypercholesterolemia treatment: a new hypothesis or just an accident? Med Hypotheses 2002 59(6):751-6.